Researchers have announced that an experimental weight-loss medication, eloralintide, has shown promising results in clinical trials, leading to up to 20% body weight reduction in adults with obesity.
Developed by Eli Lilly, the once-weekly injectable drug demonstrated significant weight loss and improvements in cardiometabolic risk factors, although experts caution that further studies are needed before it can be approved for widespread use.